Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis

Ernest Choy, Roberto Caporali, Ricardo Xavier, Bruno Fautrel, Raimon Sanmarti, Min Bao, Jenny Devenport, Attila Pethö-Schramm, Ernest Choy, Roberto Caporali, Ricardo Xavier, Bruno Fautrel, Raimon Sanmarti, Min Bao, Jenny Devenport, Attila Pethö-Schramm

Abstract

Objectives: This post hoc analysis of the TOZURA study programme evaluated the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or with concomitant conventional synthetic DMARDs (csDMARDs) in patients with RA categorized by baseline glucocorticoid (GC) use.

Methods: TOZURA was a multinational, open-label, single-arm, common-framework study programme (11 protocols, 22 countries) in patients with moderate to severe RA in whom csDMARDs or biologic therapies had failed or who were MTX naïve. Patients received once-weekly TCZ-SC 162 mg for ⩾24 weeks as monotherapy or in combination with csDMARDs and/or oral GC use (⩽10 mg/day prednisone or equivalent), which was to be continued unchanged for 24 weeks. Treatment subgroups were defined by baseline GC use and analysed for efficacy and safety.

Results: Of 1804 patients who received TCZ-SC, 145 received monotherapy + GC, 208 received monotherapy without GC, 730 received combination therapy + GC and 721 received combination therapy without GC. The median GC dose in both GC subgroups was 5 mg/day. The proportion of patients who achieved clinical remission, defined as DAS in 28 joints using ESR <2.6, increased similarly from baseline to week 24 in all subgroups. Improvements in patient-reported outcomes were similar in all subgroups. Overall adverse event profiles were generally similar between subgroups, with some slight numerical differences between GC and non-GC subgroups.

Conclusion: The incremental efficacy benefits of TCZ-SC as monotherapy and in combination with csDMARDs were similar between patients with and without previous and continued oral GC treatment, with generally similar safety profiles.

Trial registration: ClinicalTrials.gov, http://www.clinicaltrials.gov, NCT01941940, NCT01941095, NCT01951170, NCT01987479, NCT01988012, NCT01995201, NCT02001987, NCT02011334, NCT02031471, NCT02046603, NCT02046616.

Keywords: RA; biologic therapies; csDMARDs; glucocorticoid; tocilizumab.

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

Fig . 1
Fig. 1
Efficacy of TCZ-SC over 24 weeks in subgroups of patients with RA treated with TCZ-SC Percentage of patients in clinical remission (DAS28-ESR A) TCZ-SC monotherapy or (B) TCZ-SC + csDMARD. TJC28 over 24 weeks in subgroups of patients with RA treated with TCZ-SC in subgroups of patients with RA treated with (C) TCZ-SC monotherapy or (D) TCZ-SC + csDMARD. SJC28 over 24 weeks in subgroups of patients with RA treated with (E) TCZ-SC monotherapy or (F) TCZ-SC + csDMARD. csDMARD: conventional synthetic DMARD; DAS28-ESR: DAS in 28 joints using ESR; GC: glucocorticoid; SJC28: swollen joint count in 28 joints; TCZ-SC: subcutaneous tocilizumab; TJC28: tender joint count in 28 joints.
Fig . 2
Fig. 2
FACIT-F score over 24 weeks in subgroups of patients with RA treated with (A) TCZ-SC monotherapy or (B) TCZ-SC + csDMARD csDMARD: conventional synthetic DMARD; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; GC: glucocorticoid; TCZ-SC: subcutaneous tocilizumab.
Fig . 3
Fig. 3
HAQ-DI score over 24 weeks in subgroups of patients with RA treated with (A) TCZ-SC monotherapy or (B) TCZ-SC + csDMARD csDMARD: conventional synthetic DMARD; GC: glucocorticoid; HAQ-DI: HAQ-Disability Index; TCZ-SC: subcutaneous tocilizumab.

References

    1. Scott DL, Wolfe F, Huizinga TW.. Rheumatoid arthritis. Lancet 2010;376:1094–108.
    1. Strand V, Khanna D.. The impact of rheumatoid arthritis and treatment on patients’ lives. Clin Exp Rheumatol 2010;28:S32–40.
    1. Caplan L, Wolfe F, Russell AS, Michaud K.. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007;34:696–705.
    1. Best JH, Kong AM, Lenhart GM. et al. Association between glucocorticoid exposure and healthcare expenditures for potential glucocorticoid-related adverse events in patients with rheumatoid arthritis. J Rheumatol 2018;45:320–8.
    1. Wilson JC, Sarsour K, Gale S. et al. Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2018; Advance Access published 1 June 2018, doi: 10.1002/acr.23611.
    1. Charles-Schoeman C, van der Heijde D, Burmester GR. et al. Effect of glucocorticoids on the clinical and radiographic efficacy of tofacitinib in patients with rheumatoid arthritis: a posthoc analysis of data from 6 phase III studies. J Rheumatol 2018;45:177–87.
    1. Eulenfeld R, Dittrich A, Khouri C. et al. Interleukin-6 signalling: more than Jaks and STATs. Eur J Cell Biol 2012;91:486–95.
    1. Smolen JS, Beaulieu A, Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97.
    1. Genovese MC, McKay JD, Nasonov EL. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968–80.
    1. Emery P, Keystone E, Tony HP. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23.
    1. Jones G, Sebba A, Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88–96.
    1. Kremer JM, Blanco R, Brzosko M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609–21.
    1. Burmester GR, Rubbert-Roth A, Cantagrel A. et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69–74.
    1. Kivitz A, Olech E, Borofsky M. et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:1653–61.
    1. Ogata A, Tanimura K, Sugimoto T. et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:344–54.
    1. Burmester GR, Rubbert-Roth A, Cantagrel A. et al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis 2016;75:68–74.
    1. Kivitz A, Olech E, Borofsky MA. et al. The efficacy and safety of tocilizumab subcutaneous Q2W and following escalation from Q2W to QW therapy in combination with traditional Dmards in patients with moderate to severe rheumatoid arthritis at 96 weeks. Arthritis Rheumatol 2014;66:S1076–7.
    1. Ogata A, Amano K, Dobashi H. et al. Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI study. J Rheumatol 2015;42:799–809.
    1. Kivitz A, Wallace T, Olech E. et al. Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term extension study. Rheumatol Ther 2016;3:291–304.
    1. Choy E, Caporali R, Xavier R. et al. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology 2018;57:499–507.
    1. Safy M, Jacobs JWG, Edwardes M. et al. SAT0169 No evidence that concomitant glucocorticoid therapy affects efficacy and safety of tocilizumab monotherapy in rheumatoid arthritis clinical trials. Ann Rheum Dis 2018;77(Suppl 2):945.
    1. Ferreira RJO, Duarte C, Ndosi M. et al. Suppressing inflammation in rheumatoid arthritis: does patient global assessment blur the target? A practice-based call for a paradigm change. Arthritis Care Res (Hoboken) 2018;70:369–78.
    1. Buttgereit F, Mehta D, Kirwan J. et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013;72:204–10.
    1. De Vries F, Bracke M, Leufkens HG. et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007;56:208–14.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe